Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRI-002 in mild cognitive impairment or mild dementia due to Alzheimer's disease
NL-OMON59032Phase 2Completed
- Sponsor
- PRInnovation GmbH
- Start
- Dec 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PRI-002 in Alzheimer's disease (AD), sponsored by PRInnovation GmbH. Started Dec 2023; status: completed.
02
Drugs
PRI-002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON59032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59032.